

PERSONAL INFORMATION

First Name: Georgios

Last Name: Zarkavelis

Date of Birth: 14/03/1984

Address Tekmonos 76, 45221, Ioannina Greece

Mobile Phone Number: +30 6973044661

E mail: gzarkavelis@outlook.com.

HOSPITAL ADDRESS (Current Position)

Hospital:	University Hospital of Ioannina		
Clinic	Oncology Department		
/Department:			
Street:	StavrouNiarchouAvenue	Number:	N/A
Postal Code:	45500		
City:	Ioannina		
Country:	Greece		
Telephone	+30 2651099394	Fax Number:	+30 2651099394
Number:			
Mobile:	+306973044661		
E-mail Address:	gzarkavelis@outlook.com		

ACADEMIC QUALIFICATIONS

09/2001-12/2007 Medical School, National and Kapodistrian University of Athens, Medical Doctor. (MD)

09/2012-06/2016 School Of Economics, Open University of Cyprus, Master of Science in Health Politics and Health services. (MSc)

04/2015-07/2019 Medical School, University of Ioannina, Phd in Medical Oncology. Phd Thesis: "Detection of mutated KRAS gene and its transcriptome in cell free DNA and platelets in colorectal cancer patients and investigation of its utility for disease monitoring."

03/2020-ongoing Post doctorate researcher, School of Medicine, University of Ioannina. Thesis: Biomarkers in peripheral blood and in tissue-application of liquid biopsy as complementary method to tissue biopsies.

PROFESSIONAL EXPERIENCE

04/2009-04/2010 General Hospital of Agrinio, Greece, Doctor in Primary Care Services.

02/2011-10/2011 492 Military Hospital of Alexandroupolis, Greece, fulfilling military services.

01/2012-01/2014 University Hospital of Patras, Greece, Internal Medicine Clinic, Resident in Internal Medicine

01/2014-07/2014 University Hospital of Patras, Greece, Hematology Clinic- Bone Marrow Transplantation Unit, Resident in Hematology.

10/2014-11/2017 University Hospital of Ioannina, Greece, Medical Oncology Clinic, Resident in Medical Oncology.

11/2017-ongoing University Hospital of Ioannina, Greece, Medical Oncology Clinic, Specialist in Medical Oncology.

AWARDS-GRANTS

Financial Grant in 2016-2017 by the Hellenic society of Medical Oncology for the scientific research programme: "Detection of mutated KRAS gene and its transcriptome in cell free DNA in colorectal cancer patients and investigation of its utility for disease monitoring."

Award for oral presentation of : "AMALTHEA: A prospective, single-arm study of the Hellenic Cooperative Oncology Group (HeCOG) evaluating the efficacy and safety of 1st line , FOLFIRI+Aflibercept for six months followed by aflibercept maintenance in patients with metastatic colorectal cancer." May 2018, Thessaloniki, Congress of the Hellenic society of Medical Oncology (HESMO), May 2018

PARTICIPATION IN CLINICAL TRIALS

Study Name or Code	Participation Period (total in years)	Role in the study (Principal Investigator or Sub-Investigator or Study Coordinator or Other, specify)	Therapeutic Area:	Clinical Phase (Phase I, II, III, IV)	Study Status (In Progress or Closed)
MO29112	Sep 2015-Feb 20	SI	CRC	III	Closed
20120286	Oct 2015-May 2019	SI	CRC	Observational	Closed
NEPTUNE	Jan 2016-Jul 21	SI	Lung	III	Closed

20130232	Mar 2016-Jul 19	SI	SCCHN	I	Closed
20110265	Jun 2016-Jun 21	SI	Melanoma	III	Closed
Premise	Jul 2016-Nov 2019	SI	Prostate	Observational	Closed
A-96-52030-737 G- NET	JUL 2017-Feb2019	SI	G-NET	Observational	In progress
CA209-901	Oct2017-con	SI	Urothelial	III	In progress
HE37/12	16/3/2017-Oct 2018	SI	Cholangio	II	Closed
HE6A/13(AMALTHEA)	13/7/2015-Oct2017	SI	CRC	II	Closed
HE7/12(AGAPP)	30/3/2015-Jul 2019	SI	Gastric	II	Closed
HE6B/16(A-REPEAT)	Nov2017-May 2022	SI	CRC	II	Closed
ERASMUS	Nov2017-Jul 22	SI	CRC	observational	Closed
CLEE011A2404	DEC2017-con	SI	Breast	III β	Closed
TAHOE	DEC2017-Sep 2019	SI	Lung	III	Closed
MERU	JAN2018-Mar 2020	SI	Lung	III	Closed
CA209-649	Jan2018-Oct 2021	SI	Gastric	III	Closed
I3Y-MC-JPFC	AUG2018-con	SI	BREAST	III	In progress
MX39795	SEP2018-con	SI	CUP	II	In progress

Debio 1347-201	May 19-Jul 20	SI	SOLID TUMORS	II	Closed
IMMU 132-13	May 22-cont	SI	UROTHELIAL	III	In progress
GO 42784	Mar 2022-cont	SI	BREAST	III	In progress
NAPOLI US 6001-001	Jun 21-cont	SI	PANCREAS	III	In progress
AVION	Feb 22-cont	SI	RENAL	Observational	In progress
HORIZON	Jun 2021-cont	SI	LUNG	Observational	In progress
PROSPECT	Feb 22-cont	SI	PROSTATE	Observational	In progress
INFINITY	Oct 21-cont	SI	LUNG	Observational	In progress

RESEARCH ACTIVITIES

03/2020-ongoing Post doctorate researcher, School of Medicine, University of Ioannina. Thesis: Biomarkers in peripheral blood and in tissue-application of liquid biopsy as complementary method to tissue biopsies.

Member of the ESMO MCBS extended Working Group which focuses on improved decision-making regarding the value of anti-cancer therapies, promotes accessibility and reduces inequity of access to high value cancer treatments.

Member of the ESMO CME Working Group . The goal of the ESMO CME Working group is to :

- ✓ Assess and accredit educational events, conferences and congresses

- ✓ Assess and accredit distance learning activities
- ✓ Supervise the ESMO-MORA system of continuing medical education (ESMO Medical Oncologist's Recertification Approval), assessing conflicting cases
- ✓ Identify and formulate new CME opportunities

Participation in Horizon European program 2020 Call: H2020-SC1-DTH-2018-2020 (Digital transformation in Health and Care) Topic: SC1-DTH-01-2019, Type of action: RIA, Proposal number: 875361, Cardiocare

Member of the COVID international multidisciplinary oncology consortium involving 48 physicians from 27 countries, the ECPC (European Cancer patient Coalition) and the FAVO (Federation of associations of voluntaries in oncology). Both ECPC and FAVO representing more than 500 affiliated institutions at international and national level. Aim of the group is to rationalize the COVID measures in order to ameliorate both information and services both for oncology patients and cancer professionals. The Group began its activities in March 2020. Results of the research and activities of the COVID international multidisciplinary oncology consortium had been already published in (*Lancet Oncology* 2020, *JBUON* 2020, *Frontiers Oncology* 2020)

Member of the Hellenic Cooperative Oncology Group, with main research focus the neoplasms of gastrointestinal tract.

Member of EMEKEN (Society for Study of Clonal Heterogeneity of Neoplasia) that aims at studying the biology and clonal heterogeneity of cancer, conducting and supporting basic, translational, applied and clinical research into cancer. It also develops and supports new innovative diagnostic and therapeutic approaches for cancer patients.

TEACHING EXPERIENCE

2019-2020 Course: Internal Medicine II, University of Ioannina, Nursing School, 5th semester of studies, full teaching

2021-2021 Course: Internal Medicine II, University of Ioannina, Nursing School, 5th semester of studies, full teaching

2021-2022 Course: Medical Oncology, University of Ioannina, Medical School, 9th semester of studies, full teaching

2017-2020 Course: Medical Oncology, University of Ioannina, Medical School, 9th semester of studies, 2 hours lecture on “Gastrointestinal Neoplasms”

2017-2019 Lecture in Nursing Subspecialties Education, University Hospital of Ioannina, 2 hours lecture each year on “Current issues in Medical Oncology”

2017-2022 2 hours lecture each year on “Liquid Biopsies” in postgraduate master’s program “Clinical Chemistry”, Medical School, University of Ioannina

2021-2022 2-hour lecture on “Liquid Biopsies” in postgraduate master’s program “Classic and emerging biomarkers in chronic diseases”, Medical School, University of Ioannina

2019-2022 2-hour each year lecture on “Liquid Biopsies” in postgraduate master’s program “Molecular cellular biology and biotechnology”, course : “ Molecular oncology, cell growth , differentiation and cancer”, Medical School, University of Ioannina

2021 preparation of the E-Module “Optimising Outcomes For Patients With Advanced Colorectal Cancer “, ESMO Oncology PRO E-Learning project 2021

SELECT PUBLICATIONS

Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG). Zarkavelis G, Kotoula V, Kolliou GA, Papadopoulou K, Tikas I, Karavasilis V, Samantas E, Dervenis C, Efstratiou I, Nicolaou I, Apessou D, Kafiri G, Koletsa T, Bompolaki I, Rallis G, Batistatou A, Glantzounis G, Pectasides D, Fountzilias G, Pentheroudakis G. ESMO Open. 2019 Sep 18;4(5):e000525. doi: 10.1136/esmoopen-2019-000525. eCollection 2019.

Current and future biomarkers in colorectal cancer. Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G. Ann Gastroenterol. 2017;30(6):613-621. doi: 10.20524/aog.2017.0191. Epub 2017 Sep 22.

Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review. Zarkavelis G, Kollas A, Kampletsas E, Vasiliou V, Kaltsonoudis E, Drosos A, Khaled H, Pavlidis N.J Adv Res. 2016 Sep;7(5):719-726. doi: 10.1016/j.jare.2016.04.001. Epub 2016 Apr 23

Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat? Kastrisiou M, Zarkavelis G,

Pentheroudakis G, Magklara A. *Cancers (Basel)*. 2019 Oct 16;11(10). pii: E1573. doi: 10.3390/cancers11101573.

How I treat cancers of unknown primary. Zarkavelis G, Mauri D, Pentheroudakis G. *ESMO Open*. 2019 May 10;4(Suppl 2):e000502. doi: 10.1136/esmoopen-2019-000502. eCollection 2019. Review. No abstract available.

TAILORing targeted therapies to the right patient at the right time: how close are we? Zarkavelis G, Pentheroudakis G. *Ann Transl Med*. 2018 Nov;6(Suppl 1): S87. doi: 10.21037/atm.2018.10.75.

Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarker—possible diagnostic missteps trusting a single method. Ioanna Gazouli, **George Zarkavelis**, Davide Mauri, George Pentheroudakis, *Ann Transl Med* 2019. doi: 10.21037/atm.2019.09.144

AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. Zarkavelis G, Samantas E, Koliou GA, Papadopoulou K, Mauri D, Aravantinos G, Batistatou A, Pazarli E, Tryfonopoulos D, Tsipoura A, Bobos M, Psyrris A, Makatsoris T, Petraki C, Pectasides D, Fountzilas G, Pentheroudakis G. *Acta Oncol*. 2021 May 18:1-9. doi: 10.1080/0284186X.2021.1912822. Online ahead of print. PMID: 34003074

Development and Validation of a Targeted 'Liquid' NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer Myrto Kastrisiou , George Zarkavelis , Anastasia Kougioumtzi , Prodromos Sakaloglou , Charilaos Kostoulas , Ioannis Georgiou , Anna Batistatou , George Pentheroudakis , Angeliki Magklara *Diagnostics (Basel)*. 2021 Dec 16;11(12):2375. doi: 10.3390/diagnostics11122375.

Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials. Mauri D, Zarkavelis G, Filis P, Tsali L, Zafeiri G, Papadaki A, Vassou A, Georgopoulos C, Pentheroudakis G. *ESMO Open*. 2018 Jun 23;3(4):e000343. doi: 10.1136/esmoopen-2018-000343. eCollection 2018

PARTICIPATION IN CONGRESSES-ORGANISING COMMITTEES

Over 50 invitations and participations as invited speaker in national and international congresses.

Over 30 announcements in national and international congresses

Continuous medical education: Attendance of more than 40 national and international congresses since 2017

Member of the organizing Committee of 8 oncology congresses

Member of the organizing committee for evaluation of scientific research projects submitted to 6th Hellenic Congress of Oncology, May 2022, Thessaloniki, Greece

LANGUAGES

Greek: Mother Tongue

English: Certificate of Proficiency in English, University of Cambridge, C2

German: Zertifikat Deutsch als Fremdsprache, Goethe Institut, B1

MEMBERSHIPS

ESMO

HeCOG

EOPE

EMEKEN (Society for the study of clonal heterogeneity of neoplasia)